MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
57.32
+1.45
+2.60%
Opening 13:21 07/24 EDT
OPEN
56.32
PREV CLOSE
55.87
HIGH
57.36
LOW
56.21
VOLUME
1.05M
TURNOVER
--
52 WEEK HIGH
86.74
52 WEEK LOW
40.03
MARKET CAP
9.47B
P/E (TTM)
-27.2797
1D
5D
1M
3M
1Y
5Y
1D
Morgan Stanley Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
TipRanks · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Arrowhead Pharmaceuticals (ARWR) and Insight Molecular Diagnostics (IMDX)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Ionis Pharmaceuticals (IONS) and Repligen (RGEN)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Claritev (CTEV), Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR)
TipRanks · 1d ago
Ionis Buy Rating Reaffirmed as TRYNGOLZA Lead and Competitive Edge Support Unchanged $125 Price Target
TipRanks · 1d ago
Ionis Pharmaceuticals (IONS) Gets a Buy from Barclays
TipRanks · 1d ago
Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential
Seeking Alpha · 2d ago
Arrowhead hits 52-week high as late-stage trial win marks “derisking event”
Seeking Alpha · 2d ago
More
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.